Compare CVS Health Corp (CVS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs BIO-TECHNE Corp — how do they compare? CVS Health Corp trades at $86.16 (market cap $112.29B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: CVS Health Corp is far larger — about 9.9× BIO-TECHNE Corp's market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and BIO-TECHNE Corp for 64 Days on average.
| CVS | TECH | |
|---|---|---|
Market Cap | $112.29B | $11.36B |
Volume | 7,763,676 | 5,390,331 |
Sector | Health | Health |
52-Week High | $110.60 | $72.61 |
52-Week Low | $70.08 | $43.31 |
Typical Hold Time | 83 Days | 64 Days |
Enterprise Value | $174.64B | $11.39B |
Dividend Yield | 3.03% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, down 0.17% on the day, with a bearish technical signal and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.58 exceeding the $1.85 estimate. Revenue grew to $402.07B in 2025, though net income margin compressed to 1.18%. Recent news highlights Aetna's 2027 Medicare plan updates and a quarterly dividend declaration.
CVS presents a mixed outlook with solid revenue growth and analyst bullishness (85% buy ratings, $111.20 consensus target) offset by profitability pressures and a bearish technical trend. Key risks include reimbursement pressure and ongoing legal investigations, but the stock offers value with a low P/S of 0.27 and dividend yield support.
TECH trades at $72.45, near its 52-week high of $72.70 (Defense World, 2026-09-28), with a slight 0.11% decline over 24 hours. The stock shows a bullish technical signal, supported by moving averages, while fundamentals reveal a high P/E of 62.46 and net income margin of 14.97% for 2025. Recent news highlights shareholder approval of its acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23), a key catalyst for near-term price action.
The outlook is mixed: the acquisition offers upside to the current price, but elevated valuation ratios pose risks if earnings growth falters. Analyst consensus is divided with 46% buy ratings, and net income volatility from 2022-2025 signals execution challenges. Investors should weigh the acquisition premium against fundamental sustainability in a competitive life sciences tools sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
